Gentibio details development, characterization of novel autologous engineered human regulatory T-cell therapy for T1D
Oct. 17, 2022
Preclinical data on a novel T-cell therapy based on engineered autologous regulatory T cells (GNTI-122, EngTregs) for the potential treatment of type 1 diabetes (T1D) were presented by Gentibio Inc.
